9888À­Ë¹Î¬¼Ó˹

9888À­Ë¹Î¬¼Ó˹(¹É·Ý)ÓÐÏÞ¹«Ë¾-¹Ù·½ÍøÕ¾
ÎÒÃǵķþÎñ

×÷ΪÖйúµÚÈý·½¼ì²âÓëÈÏÖ¤·þÎñµÄ¿ªÍØÕߺÍÁìÏÈÕߣ¬CTI9888À­Ë¹Î¬¼Ó˹¼ì²âΪȫÇò¿Í»§ÌṩһվʽĥÁ·¡¢²âÊÔ¡¢Ð£×¼¡¢ÈÏÖ¤¼°ÊÖÒÕ·þÎñ¡£

9888À­Ë¹Î¬¼Ó˹(¹É·Ý)ÓÐÏÞ¹«Ë¾-¹Ù·½ÍøÕ¾
ÐÐÒµ½â¾ö¼Æ»®

·þÎñÄÜÁ¦ÒÑÖÜÈ«ÁýÕÖµ½·ÄÖ¯´ò°ç¼°Ð¬°ü¡¢Ó¤Í¯Íæ¾ß¼°¼Ò¾ÓÉúÑÄ¡¢µç×ÓµçÆ÷¡¢Ò½Ñ§¿µ½¡¡¢Ê³Îï¼°Å©²úÆ·……µÈÐÐÒµµÄ¹©Ó¦Á´ÉÏÏÂÓΡ£

9888À­Ë¹Î¬¼Ó˹(¹É·Ý)ÓÐÏÞ¹«Ë¾-¹Ù·½ÍøÕ¾
ÌØÉ«·þÎñ

ÖÜÈ«°ü¹ÜÆ·ÖÊÓëÇå¾²£¬Íƶ¯ºÏ¹æÓëÁ¢Ò죬ÕÃÏÔÆ·ÅƾºÕùÁ¦£¬ÊµÏÖ¸ü¸ßÖÊÁ¿¡¢¸ü¿µ½¡¡¢¸üÇå¾²¡¢¸üÂÌÉ«µÄ¿ÉÒ»Á¬Éú³¤¡£

¼ÓÈëÎÒÃÇ
È˲ÅÕþ²ß
ÕÐÏÍÄÉÊ¿
9888À­Ë¹Î¬¼Ó˹(¹É·Ý)ÓÐÏÞ¹«Ë¾-¹Ù·½ÍøÕ¾
È˲ÅÕþ²ß
°ü¹ÜÔ±¹¤»ù±¾È¨ÒæÓ븣Àû£»ÌṩרҵÊÖÒÕÅàѵ£¬Ôö½øÔ±¹¤Éú³¤£»¿ªÕ¹¸»ºñ¶à²ÊµÄ»î¶¯£¬Æ½ºâÔ±¹¤ÊÂÇéÓëÉúÑÄ¡£
9888À­Ë¹Î¬¼Ó˹(¹É·Ý)ÓÐÏÞ¹«Ë¾-¹Ù·½ÍøÕ¾
ÕÐÏÍÄÉÊ¿
½Ó´ý¼ÓÈë9888À­Ë¹Î¬¼Ó˹¼ì²â¸÷ÈËÍ¥£¬ÎÒÃǽ«ÎªÄã´î½¨Ò»¸ö³ä·ÖÑéÕ¹²Å»ª£¬ÊµÏÖÖ°ÒµÀíÏëµÄÎę̀¡£
9888À­Ë¹Î¬¼Ó˹(¹É·Ý)ÓÐÏÞ¹«Ë¾-¹Ù·½ÍøÕ¾
ÐÂÎÅ×ÊѶ

ctDNA¼×»ù»¯×÷ΪÉúÎï±ê¼ÇÎïÔÚ½áÖ±³¦°©Õï¶Ï¡¢Ô¤ºóºÍÕ¹ÍûÖеÄÓ¦ÓÃ

Ðû²¼Ê±¼ä£º2024-08-30 ä¯ÀÀ´ÎÊý£º676

½áÖ±³¦°©£¨colorectal cancer, CRC£©ÊÇ×î³£¼ûµÄÏû»¯µÀ¶ñÐÔÖ×ÁöÖ®Ò»£¬ÔçÆÚ·¢Ã÷½áÖ±³¦°©Óë¸ÄÉÆÉúÑÄЧ¹ûÇ×½üÏà¹Ø¡£ctDNA¼×»ù»¯×÷ΪһÖÖ±í¹ÛÒÅ´«ÐÞÊΣ¬ÒѾ­ÒýÆðÔ½À´Ô½¶àµÄ¹Ø×¢¡£±¾Æª×ÛÊöMethylated circulating tumor DNA as a biomarker for colorectal cancer diagnosis, prognosis, and prediction£¬ÏêϸÐðÊöÁËct DNA¼×»ù»¯×÷ΪÉúÎï±ê¼ÇÎïÔÚ½áÖ±³¦°©Õï¶Ï¡¢Ô¤ºóºÍÕ¹ÍûÖеÄÓ¦Óá£

 

9888À­Ë¹Î¬¼Ó˹(¹É·Ý)ÓÐÏÞ¹«Ë¾-¹Ù·½ÍøÕ¾


    ÔÚ¶à¸öÑо¿Öз¢Ã÷µÄ½áÖ±³¦°©¼ì²âµÄÉúÎï±ê¼ÇÎï°üÀ¨BCAT1(Ö§Á´°±»ùËáתëÄø1)¡¢IKZF1(IKAROS¼Ò×åпָ1)¡¢SDC2(syndecan-2)¡¢ALX4(aristalless-ÑùͬԴºÐ4)¡¢SFRP2(ÉøÍ¸¾íÇúÏà¹ØÂѰ×2)¡¢OSMR(Ö×ÁöÒÖÖÆËØMÊÜÌå)¡¢SFRP1(ÉøÍ¸¾íÇúÏà¹ØÂѰ×1)ºÍVIM(vimentin)¡£BCAT1»ùÒò±àÂëÒ»ÖÖ¼ÓÈëÖ§Á´°±»ùËáÆÊÎö´úлµÄø£¬IKZF1»ùÒò±àÂëµ÷¿Ø²¿·Öϸ°ûÖÜÆÚµ÷¿Ø»ùÒòµÄת¼Òò×Ó¡£BCAT1ºÍIKZF1¶ÔCRC¼ì²âµÄÃô¸ÐÐÔ»®·ÖΪ47.3% ~ 64.9%ºÍ48% ~ 67.6%¡£±ðµÄ£¬Ëæ×ŽáÖ±³¦°©·ÖÆÚµÄÔöÌí£¬ÑôÐÔÂÊÒ²»áÔöÌí£¬µ«ÏÙÁöµÄÑôÐÔÂʺܵÍ¡£ÁíÒ»¸öÒѱ¨µÀµÄ»ùÒòSDC2ÔÚ½áÖ±³¦°©Ï¸°ûÖÐÔö½øÏ¸°ûÔöÖ³¡¢Ç¨áãºÍÇÖÏ®£¬ÒÖÖÆÏ¸°ûµòÍö£¬¼¤»îÉÏÆ¤-¼ä³äÖÊת»¯(EMT)ºÍË¿ÁÑÔ­»î»¯ÂѰ׼¤Ã¸(MAPK)ÐźÅͨ·¡£SDC2¿ÉÄÜÊÇÒ»ÖÖºÜÊÇÓÐǰ;µÄCRC¼ì²â¼×»ù»¯±ê¼ÇÎ¶ÔËùÓн׶εÄÃô¸ÐÐÔÔÚ69 - 87%Ö®¼ä£¬¶ÔCRC»¼ÕßѪ½¬/ѪÇåµÄÌØÒìÐÔԼΪ95%¡£

 

¶àÏîÑо¿ÅúעͬʱÆÊÎö¶à¸ö¸ß¼×»ù»¯Ñ­»·DNAÔÚ¼ì²âCRC·½Ãæ±Èµ¥¸ö»ùÒò¸üÃô¸Ð¡£¶àÏîÑо¿Åú×¢£¬Ò»×麬ÓÐmSEPT9µÄ¼×»ù»¯»ùÒò¿ÉÄÜÔÚ°©Ç°²¡±äºÍÔçÆÚCRCµÄ¼ì²âÖÐÓÐÁÙ´²¼ÛÖµ¡£Í¬Ê±ÆÊÎöSEPT9ºÍSDC2ÔöÌíÁËËùÓÐ·ÖÆÚºÍÿ¸ö·ÖÆÚµÄÃô¸ÐÐÔ£¬µ«¶ÔÌØÒìÐÔûÓÐÏÔÖøÓ°Ïì¡£ÕâЩÑо¿Åú×¢¼×»ù»¯µÄSEPT9ºÍSDC2¿ÉÄÜÊÇÔçÆÚCRCɸ²éµÄ×î¼Ñ×éºÏÖ®Ò»¡£

 

9888À­Ë¹Î¬¼Ó˹(¹É·Ý)ÓÐÏÞ¹«Ë¾-¹Ù·½ÍøÕ¾


    »ùÓÚ±¾Æª×ÛÊö£¬ctDNA¼×»ù»¯×÷ΪCRCÕï¶Ï¡¢Ô¤ºóºÍÕ¹ÍûµÄÑ­»·ÉúÎï±ê¼ÇÎï¾ßÓкܺõÄÔ¶¾°¡£´ó¹æÄ£µÄÁÙ´²ÊÔÑéºÍÑé֤˵Ã÷ctDNA¼×»ù»¯¿ÉÒÔ¸ÄÉÆCRCµÄÔçÆÚ·¢Ã÷ºÍ»¼ÕßµÄÕչ˻¤Ê¿ºÍ¼à²â¡£

 

²Î¿¼ÎÄÏ×

Clin Epigenetics. 2021 May 17;13(1):111.doi: 10.1186/s13148-021-01095-5.

ÍøÕ¾µØÍ¼